Current status: Answered by Jenni Minto on 31 March 2025
To ask the Scottish Government what steps it is taking to ensure that all patients across Scotland who have Parkinson’s disease have equal access to all appropriate Scottish Medicines Consortium-approved therapies, taking into consideration geographical variation in access to care.
The Scottish Government is committed to increasing the availability of safe and effective medicines that people in Scotland would benefit from. The Scottish Medicines Consortium (SMC) assesses the clinical and cost effectiveness of newly licensed medicines on a once for Scotland basis and publishes advice for Health Boards to consider. It is expected that Health Board Area & Drug and Therapeutics Committees (ADTCs) will consider making a SMC recommended medicine, or an equivalent, available on their local or regional formulary for routine prescribing within 90 days of SMC advice being published.
Health Boards are expected to apply common principles and processes in the introduction of newly licensed medicines to facilitate consistency of approach to local decision-making. The decision to prescribe a medicine, and which medicine to prescribe, is entirely for the clinician in charge of a person’s care, having considered their clinical condition, their safety, and any relevant clinical guidance.